Axcan and TPG Capital Receive Antitrust Clearances in Connection With the Proposed Acquisition
January 10 2008 - 4:19PM
Marketwired
MONT-SAINT-HILAIRE, QUEBEC (NASDAQ: AXCA) announced today that
it has received early termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
relating to the proposed acquisition of Axcan by an affiliate of
TPG Capital. In addition, the Commissioner of Competition has
issued an advance ruling certificate in connection with the
proposed acquisition under the Canadian Competition Act. As a
result, the conditions to the closing of the acquisition relating
to U.S. and Canadian antitrust approvals are now satisfied.
ABOUT AXCAN PHARMA
Axcan is a leading multinational specialty pharmaceutical
company focused on gastroenterology. The Company develops and
markets a broad line of prescription products to treat a range of
gastrointestinal diseases and disorders such as inflammatory bowel
disease, irritable bowel syndrome, cholestatic liver diseases and
complications related to pancreatic insufficiency. Axcan's products
are marketed by its own specialized sales forces in North America
and Europe. Its common shares are listed on the NASDAQ Global
Market under the symbol "AXCA" and on the Toronto Stock Exchange
under the symbol "AXP".
ABOUT TPG CAPITAL
TPG Capital is the global buyout group of TPG, a leading private
investment firm founded in 1992, with more than $35 billion of
assets under management and offices in San Francisco, London, Hong
Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park,
Moscow, Mumbai, Beijing, Shanghai, Singapore and Tokyo. TPG Capital
has extensive experience with global public and private investments
executed through leveraged buyouts, recapitalizations, spinouts,
joint ventures and restructurings. Please visit www.tpg.com.
Contacts: Axcan Pharma Inc. Isabelle Adjahi Senior Director,
Investor Relations and Communications 450-467-2600 ext. 2000
www.axcan.com
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Jan 2024 to Jan 2025
